COVID-19 and the Impact on Oral Oncolytics: A Specialty Pharmacy Perspectivehttps://shieldshealthsolutions.com/content/themes/blade/images/empty/thumbnail.jpg150150Shields Health SolutionsShields Health Solutions//shieldshealthsolutions.com/content/uploads/2021/05/shields-logo-white.svg
By Claudia S. Castro, PharmD, MS, BCOP, BCGP; and Amanda Manoogian, PharmD, BCOP The prevalence of individuals living with cancer continues to rise, largely because of an aging and growing…
COVID & Oncology – The Effects on Health System Specialty Pharmacieshttps://shieldshealthsolutions.com/content/uploads/2021/06/EX089-COVID19Infographic_Oncology-1-1-1024x791.png1024791Shields Health SolutionsShields Health Solutions//shieldshealthsolutions.com/content/uploads/2021/05/shields-logo-white.svg
This blog was written by Excelera, a Shields company. Two months ago, our blog discussed the potential impacts and areas of concern for health system specialty pharmacies and COVID. However,…
Orlando Health Provides Patients with Improved Outcomes Through Increased Access to Innovative Oncology Treatments by Joining the Excelera Networkhttps://shieldshealthsolutions.com/content/uploads/2021/06/shields-blog-icon-pr-1.svg204115Shields Health SolutionsShields Health Solutions//shieldshealthsolutions.com/content/uploads/2021/05/shields-logo-white.svg
Orlando Health is the first health system in Florida to partner with Excelera®, the company behind the Excelera Network, to further optimize its specialty pharmacy services and to provide patients with increased access to limited distribution drugs (LDDs), which include innovative oncology treatments.
Excelera® and Aptitude Health Partner to Improve Oncology Patient Outcomes Through Combined Clinical Knowledge and Educationhttps://shieldshealthsolutions.com/content/uploads/2021/06/shields-blog-icon-pr-1.svg204115Shields Health SolutionsShields Health Solutions//shieldshealthsolutions.com/content/uploads/2021/05/shields-logo-white.svg
Wolfe joins Excelera with significant experience in building strategic pharmaceutical manufacturer relationships for publicly traded and private organizations in the healthcare sector
New Combination Therapies for the Treatment of Chronic Lymphocytic Leukemiahttps://shieldshealthsolutions.com/content/themes/blade/images/empty/thumbnail.jpg150150Shields Health SolutionsShields Health Solutions//shieldshealthsolutions.com/content/uploads/2021/05/shields-logo-white.svg
Erin Kelley, PharmD, BCOP, and Jeff Engle, PharmD, MS, Fairview Health
CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) is the most common type of leukemia in adults and accounts for approximately 37% of new leukemia cases. An estimated 20,720 new cases of and 3930 deaths from CLL will occur in the United States in 2019.